Plasmid-DNA lipid nanovaccines: An innovative approach for a better world health

Aurora García-Rendón; Adriana Garibay-Escobar; Roberto Guzmán; Armando Tejeda-Mansir

doi:10.1016/B978-0-12-813687-4.00006-2

Plasmid-DNA lipid nanovaccines: An innovative approach for a better world health

Aurora García-Rendón, Adriana Garibay-Escobar, Roberto Guzmán, Armando Tejeda-Mansir

Research output: Chapter in Book/Report/Conference proceeding › Chapter › peer-review

5 Scopus citations

Abstract

One of the most important applications of immunology has been the production of various types of vaccines. Currently, new plasmid DNA (pDNA) vaccines are been developed, given rise to more cost-effective and clean production processes. These processes involve the upstream and downstream stages to produce, isolate, and purify the pDNA. The effectiveness of pDNA vaccines against pathogen microorganisms and cancer cells has been demonstrated in clinical assays and in commercial veterinary vaccines. However, low transfection efficiency and brief transgene expression have been attained in some trials. The use of cationic lipid-based nanoparticles to avoid these problems is an alternative approach that has been tested clinically. This chapter provides a summary of the advances and major challenges associated with the fusion of pDNA production technology and nanoparticle delivery technologies to produce pDNA lipid nanovaccines.

Original language	English
Title of host publication	Lipid Nanocarriers for Drug Targeting
Publisher	Elsevier
Pages	231-267
Number of pages	37
ISBN (Electronic)	9780128136874
ISBN (Print)	9780128136881
DOIs	https://doi.org/10.1016/B978-0-12-813687-4.00006-2
State	Published - 1 Jan 2018

Bibliographical note

Publisher Copyright:
© 2018 Elsevier Inc. All rights reserved.

Keywords

Bioprocesses
Liposomes
Nanoparticles
Nanovaccines
Plasmid DNA
Vaccines

Access to Document

10.1016/B978-0-12-813687-4.00006-2

Cite this

@inbook{5f49e72c37d848b5b5b33c2d5861c38e,

title = "Plasmid-DNA lipid nanovaccines: An innovative approach for a better world health",

abstract = "One of the most important applications of immunology has been the production of various types of vaccines. Currently, new plasmid DNA (pDNA) vaccines are been developed, given rise to more cost-effective and clean production processes. These processes involve the upstream and downstream stages to produce, isolate, and purify the pDNA. The effectiveness of pDNA vaccines against pathogen microorganisms and cancer cells has been demonstrated in clinical assays and in commercial veterinary vaccines. However, low transfection efficiency and brief transgene expression have been attained in some trials. The use of cationic lipid-based nanoparticles to avoid these problems is an alternative approach that has been tested clinically. This chapter provides a summary of the advances and major challenges associated with the fusion of pDNA production technology and nanoparticle delivery technologies to produce pDNA lipid nanovaccines.",

keywords = "Bioprocesses, Liposomes, Nanoparticles, Nanovaccines, Plasmid DNA, Vaccines",

author = "Aurora Garc{\'i}a-Rend{\'o}n and Adriana Garibay-Escobar and Roberto Guzm{\'a}n and Armando Tejeda-Mansir",

year = "2018",

month = jan,

day = "1",

doi = "10.1016/B978-0-12-813687-4.00006-2",

language = "Ingl{\'e}s",

isbn = "9780128136881",

pages = "231--267",

booktitle = "Lipid Nanocarriers for Drug Targeting",

publisher = "Elsevier",

address = "Pa{\'i}ses Bajos",

}

TY - CHAP

T1 - Plasmid-DNA lipid nanovaccines

T2 - An innovative approach for a better world health

AU - García-Rendón, Aurora

AU - Garibay-Escobar, Adriana

AU - Guzmán, Roberto

AU - Tejeda-Mansir, Armando

PY - 2018/1/1

Y1 - 2018/1/1

N2 - One of the most important applications of immunology has been the production of various types of vaccines. Currently, new plasmid DNA (pDNA) vaccines are been developed, given rise to more cost-effective and clean production processes. These processes involve the upstream and downstream stages to produce, isolate, and purify the pDNA. The effectiveness of pDNA vaccines against pathogen microorganisms and cancer cells has been demonstrated in clinical assays and in commercial veterinary vaccines. However, low transfection efficiency and brief transgene expression have been attained in some trials. The use of cationic lipid-based nanoparticles to avoid these problems is an alternative approach that has been tested clinically. This chapter provides a summary of the advances and major challenges associated with the fusion of pDNA production technology and nanoparticle delivery technologies to produce pDNA lipid nanovaccines.

AB - One of the most important applications of immunology has been the production of various types of vaccines. Currently, new plasmid DNA (pDNA) vaccines are been developed, given rise to more cost-effective and clean production processes. These processes involve the upstream and downstream stages to produce, isolate, and purify the pDNA. The effectiveness of pDNA vaccines against pathogen microorganisms and cancer cells has been demonstrated in clinical assays and in commercial veterinary vaccines. However, low transfection efficiency and brief transgene expression have been attained in some trials. The use of cationic lipid-based nanoparticles to avoid these problems is an alternative approach that has been tested clinically. This chapter provides a summary of the advances and major challenges associated with the fusion of pDNA production technology and nanoparticle delivery technologies to produce pDNA lipid nanovaccines.

KW - Bioprocesses

KW - Liposomes

KW - Nanoparticles

KW - Nanovaccines

KW - Plasmid DNA

KW - Vaccines

UR - http://www.scopus.com/inward/record.url?scp=85059523243&partnerID=8YFLogxK

U2 - 10.1016/B978-0-12-813687-4.00006-2

DO - 10.1016/B978-0-12-813687-4.00006-2

M3 - Capítulo

AN - SCOPUS:85059523243

SN - 9780128136881

SP - 231

EP - 267

BT - Lipid Nanocarriers for Drug Targeting

PB - Elsevier

ER -

Plasmid-DNA lipid nanovaccines: An innovative approach for a better world health

Abstract

Bibliographical note

Keywords

Access to Document

Other files and links

Fingerprint

Cite this